Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19

Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19

BackgroundThe most severe cases of Coronavirus-Disease-2019 (COVID-19) develop into Acute Respiratory Distress Syndrome (ARDS). It has been proposed that oxygenation may be inhibited by extracellular deoxyribonucleic acid (DNA) in the form of neutrophil extracellular traps (NETs). Dornase alfa (Pulm...

Full description

Bibliographic Details
Main Authors: Zachary M. Holliday, Alexander P. Earhart, Mohammed M. Alnijoumi, Armin Krvavac, Lee-Ann H. Allen, Adam G. Schrum
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Immunology
Subjects:
pneumonia
viral
respiratory failure
ARDS
COVID - 19
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.714833/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.714833/full

Similar Items